Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.09 and traded as low as $4.62. Bolt Biotherapeutics shares last traded at $4.6830, with a volume of 4,843 shares traded.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price target for the company. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $34.67.

Bolt Biotherapeutics Stock Down 0.8%

The firm’s 50-day moving average price is $4.79 and its 200-day moving average price is $5.09. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51. The company has a market cap of $8.99 million, a price-to-earnings ratio of -0.29 and a beta of 1.12.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $1.50 million. Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%. Sell-side analysts forecast that Bolt Biotherapeutics, Inc. will post -11.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T3 Companies LLC purchased a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $208,000. Renaissance Technologies LLC raised its stake in shares of Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after purchasing an additional 26,400 shares during the period. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics during the fourth quarter worth $112,000. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics in the third quarter valued at $89,000. Finally, Shay Capital LLC acquired a new stake in Bolt Biotherapeutics during the 3rd quarter valued at $85,000. 86.70% of the stock is owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.